GSK has offloaded a corporate venture unit that invests in bioelectronic startups working on neuromodulation, wearables, implanted devices and other technology, Endpoints News has learned. The VC unit, Action Potential Venture Capital (APVC), launched with $50 million from GSK in 2013, when it made its first investment in SetPoint Medical, creator of an implantable device to assuage inflammatory diseases.
SR One, healthcare investor Revelation Partners and other undisclosed limited partners are backing a new, separate entity from APVC, called Synapse Fund.